Lerpin

Lercanidipine, the active ingredient in Lerpin, is a calcium channel blocker presented as an oral tablet for oral use. It treats essential hypertension in adult patients. GNH USA supplies Lerpin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is used to manage high blood pressure by acting on the vascular smooth‑muscle system. - Essential hypertension: lowers systolic and diastolic blood pressure to target levels. - Primary hypertension: helps achieve recommended blood pressure control in adults. - Elevated blood pressure: contributes to reduction of cardiovascular risk associated with sustained hypertension.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: sensation of warmth, especially on the face. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of lips, tongue, or airway. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzymes. - Severe allergic reaction: rash, itching, or anaphylaxis. - Cardiac conduction disturbances: heart block or arrhythmia.

Before initiating therapy with Lerpin, consider the following safety measures. - Blood pressure monitoring: check baseline and periodic readings. - Abrupt discontinuation: avoid stopping suddenly to prevent rebound hypertension. - Hepatic impairment: use with caution; dose adjustment may be required. - Elderly patients: start at low dose and monitor for orthostatic effects. - Concomitant CYP3A4 inhibitors: assess risk of increased drug exposure. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lerpin can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations. - Co‑administration with other potent antihypertensives: can cause additive hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Grapefruit juice: can increase drug exposure. - Diuretics: may enhance orthostatic hypotension. - Beta‑blockers: may mask tachycardia signs.